Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11982030 | 0.87 | CYP2D6 (0.69) | CYP2D6KDM4E | |
| SCHEMBL103627 | 0.83 | — | — | |
| SCHEMBL10794688 | 0.83 | TSHR (0.46) | CYP2D6TSHRTDP1 | |
| SCHEMBL12518284 | 0.82 | CYP2D6 (0.41) | CYP2D6 | |
| SCHEMBL19880130 | 0.82 | CYP2D6 (0.41) | CYP2D6 | |
| Hydrochloric Acid SCHEMBL9718071 | 0.80 | — | — | |
| SCHEMBL7886739 | 0.79 | CYP2D6 (0.50) | CYP2D6KDM4ETSHRTDP1 | |
| SCHEMBL11982015 | 0.77 | CYP2D6 (0.47) | CYP2D6KDM4ETSHRTDP1 | |
| SCHEMBL13900814 | 0.77 | CYP2D6 (0.33) | CYP2D6TSHRTDP1 | |
| SCHEMBL11454943 | 0.77 | CYP2D6 (0.40) | CYP2D6TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024119098-A1 | LIPID NANOPARTICLE (LNP) DELIVERY SYSTEMS AND FORMULATIONS | PRIME MEDICINE, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20230339929-A1 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4219718-A2 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023078277-A1 | INTERMEDIATE OF POLYAMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 武汉武药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| WO-2022129397-A1 | N-BENZYL-ALPHA-AMINOAMIDES AS ANAPHASE-PROMOTING COMPLEX/CYCLOSOME (APC/C) INHIBITORS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2022-06-23 | — | — | WO | disclosed |
| EP-3865152-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | Eubulus Biotherapeutics Inc. (CN) | 2021-08-18 | — | — | EP | disclosed |
| EP-3757215-A2 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200071591-A1 | SYNTHETIC FUNCTIONALIZED ADDITIVES, METHODS OF SYNTHESIZING, AND METHODS OF USE | ARAMCO SERVICES COMPANY (US) | 2020-03-05 | — | — | US | disclosed |
| US-10556848-B2 | Systems and methods using lanthanide halide | CALERA CORPORATION (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190119186-A1 | SYSTEMS AND METHODS USING LANTHANIDE HALIDE | CALERA CORPORATION | 2019-04-25 | — | — | US | disclosed |
| US-20150315594-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| WO-2015136018-A1 | COATING COMPOSITION | AKZO NOBEL COATINGS INTERNATIONAL B.V. (NL) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015081284-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| EP-2500349-B1 | Synthetic LTA mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections | Universitätsklinikum Freiburg (DE) | 2015-05-06 | — | — | EP | disclosed |
| WO-2012177986-A2 | CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS | VYOME BIOSCIENCES (IN) | 2012-12-27 | — | — | WO | disclosed |
| EP-2500349-A1 | Synthetic LTA mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections | Universitätsklinikum Freiburg (DE) | 2012-09-19 | — | — | EP | disclosed |
| WO-2012119846-A1 | SYNTHETIC LTA MIMETICS AND USE THEREOF AS VACCINE COMPONENT FOR THERAPY AND/OR PRO-PHYLAXIS AGAINST GRAM-POSITIVE INFECTIONS | Universitätsklinikum Freiburg (DE) | 2012-09-13 | — | — | WO | disclosed |
| US-7498068-B2 | Liquid-crystal aligning agent, liquid-crystal alignment film comprising the same, and liquid-crystal element | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | PIERRE FABRE MEDICAMENT (FR) | 2008-07-10 | — | — | US | disclosed |
| US-20070224370-A1 | Liquid-Crystal Aligning Agent, Liquid-Crystal Alignment Film Comprising the Same, and Liquid-Crystal Element | NISSAN CHEMICALS INDUSTRIES, LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119186-A1 | SYSTEMS AND METHODS USING LANTHANIDE HALIDE | HAO2, HDHD5, HACL2 | CYP2D6 1195/4885KDM4E 3252/4885TSHR 1179/4885 |
| US-20230339929-A1 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | SLC10A1, HDGF, NHERF1 | CYP2D6 1311/4885KDM4E 3980/4885TSHR 1912/4885 |
| US-20080167313-A1 | 1,2,4-Triazine Derivatives, Preparation and Use Thereof in Human Therapy | CBR3, NOX3, RTN3 | CYP2D6 240/4885KDM4E 3738/4885TSHR 133/4885 |
| US-10556848-B2 | Systems and methods using lanthanide halide | HAO2, HDHD5, HACL2 | CYP2D6 1195/4885KDM4E 3252/4885TSHR 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.